Argenx Se (ARGX) Operating Leases (2019 - 2026)
Argenx Se's (ARGX) quarterly Operating Leases came in at $36.0 million in Q2 2026, down 99.9% YoY from $35.6 billion in Q2 2025, and little changed on a QoQ basis from $36.0 million in Q4 2025.
Argenx Se (ARGX) Operating Leases (2019 - 2026) Analysis & Trends
Argenx Se (ARGX) has 8 years of Operating Leases data on file, last reported at $36.0 million in Q2 2026.
- Quarterly Operating Leases fell 99.9% year-over-year to $36.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $36.0 million (down 99.9% YoY) and the FY2025 annual result came in at $36.0 million, down 7.82% from the prior year.
- Operating Leases steadied at $36.0 million in Q2 2026, from $36.0 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $35.6 billion in Q2 2025 to a low of $6.2 million in Q2 2022.
- A 5-year average of $4.0 billion and a median of $28.1 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2025 — Operating Leases soared 126444.99% — and 2026, when it plunged 99.9%.
- Tracing ARGX's Operating Leases over 5 years: stood at $12.4 million in 2022, then soared by 60.95% to $20.0 million in 2023, then surged by 95.26% to $39.1 million in 2024, then retreated by 7.82% to $36.0 million in 2025, then changed by 0.0% to $36.0 million in 2026.
- The last three Operating Leases figures came in at $36.0 million (Q2 2026), $36.0 million (Q4 2025), and $35.6 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.00 Mn |
| Dec 31, 2025 | 36.00 Mn |
| Jun 30, 2025 | 35.57 Bn |
| Dec 31, 2024 | 39.05 Mn |
| Jun 30, 2024 | 28.11 Mn |
| Dec 31, 2023 | 20.00 Mn |
| Jun 30, 2023 | 8.04 Mn |
| Dec 31, 2022 | 12.43 Mn |
| Jun 30, 2022 | 6.21 Mn |
| Dec 31, 2021 | 7.96 Mn |
| Jun 30, 2021 | 4.43 Mn |
| Dec 31, 2020 | 6.00 Mn |
| Jun 30, 2020 | 5.14 Mn |
| Dec 31, 2019 | 5.03 Mn |
| Jun 30, 2019 | 4.14 Mn |